Oncology Institute, Inc. (TOI)

The Oncology Institute, Inc. (TOI) stock has experienced significant positive momentum in the past six months, climbing an astonishing 1,263.46%. Key events impacting the stock price include the Third Quarter 2025 Earnings Call, where TOI reported a quarterly loss but surpassed revenue estimates and increased its full-year 2025 guidance. The company achieved Adjusted EBITDA profitability in September 2025 for the first time as a public company. Leadership promotions and the addition of a new board member were met with positive investor response. TOI reaffirmed its 2025 guidance and provided a preliminary 2026 outlook, anticipating total revenue between $630 million and $650 million. Positive analyst sentiment has also supported the stock.

Based on available data, there is a potential period of seasonal strength for TOI stock between December 1 and February 21, which has historically resulted in a geometric average return of 5.8% above the S&P 500 Total Return Index. This seasonal strength correlates poorly with the broader Healthcare sector's seasonal strength. Specific demand seasonality for TOI's products and services is not explicitly detailed, but factors such as insurance cycles, patient deductibles, and holiday periods could potentially influence demand for healthcare services.

The Oncology Institute, Inc. (TOI) is dedicated to providing comprehensive, value-based cancer care in community settings across the United States. Founded in 2007 and headquartered in Cerritos, California, TOI operates within the healthcare sector, focusing on medical care facilities and clinics/outpatient services. The company manages cancer care costs through a hybrid approach combining fixed payments for managed populations with traditional fee-for-service arrangements. TOI's services are delivered through Dispensary, Patient Services, and Clinical Trials & Other segments. Major services include physician services, in-house infusion centers and dispensaries, clinical trials, outpatient blood product transfusion and stem cell transplant services, radiation oncology services, patient support services, and palliative care programs.

The Oncology Institute, Inc. operates over 100 clinics and affiliate locations across five states, including California, Florida, and Oregon. While historically concentrated in California, recent expansions and new capitation contracts demonstrate a growing presence in other markets.

The Oncology Institute has cultivated a strong reputation for its commitment to innovation, cutting-edge therapies, and a patient-centric approach in cancer care. The company is recognized for its dedication to research and development, actively participating in clinical trials to advance cancer treatment. Events affecting TOI's reputation include the initiation of a strategic review, negative price reactions to operational announcements, leadership promotions and board additions, and the reaffirmation of guidance and path to profitability.

The ownership structure of The Oncology Institute, Inc. (TOI) includes individual, institutional, and private equity investors. Individual investors hold a significant collective stake, often around 47% of the company's shares. Institutional investors hold a substantial portion, generally between 34.42% and 37% of shares outstanding. M33 Growth, LLC is the largest single owner, holding a significant stake of 5.53% to 9.12% of shares outstanding. Oncology Institute insiders hold 35.39% of the stock.